Details of the Drug

General Information of Drug (ID: DMXLAPF)

• Drug Name: UCB-11056
• Synonyms: 127390-77-6; Ucb-11056; Ucb 11056; 2-(4-morpholino-6-propyl-1,3,5-triazin-2-yl)aminoethanol; UNII-MU6BC50P47; MU6BC50P47; 2-((4-Morpholino-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; 2-((4-(4-Morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; Ethanol,2-[[4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl]amino]-; Ethanol, 2-((4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)-; NERMEVBNTXXDNG-UHFFFAOYSA-N; ACMC-20msf9; AC1L2Y9Y; SCHEMBL3365592; CTK4B5589; DTXSID60155545; ZINC3803539

Indication

Disease Entry	ICD 11	Status	REF
Cognitive impairment	6D71	Phase 2	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 267.33
  Logarithm of the Partition Coefficient (xlogp); 0.9
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 7
• Chemical Identifiers:
  Formula: C12H21N5O2
  IUPAC Name: 2-[(4-morpholin-4-yl-6-propyl-1,3,5-triazin-2-yl)amino]ethanol
  Canonical SMILES: CCCC1=NC(=NC(=N1)N2CCOCC2)NCCO
  InChI: InChI=1S/C12H21N5O2/c1-2-3-10-14-11(13-4-7-18)16-12(15-10)17-5-8-19-9-6-17/h18H,2-9H2,1H3,(H,13,14,15,16)
  InChIKey: NERMEVBNTXXDNG-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 130928
  CAS Number: 127390-77-6
  TTD ID: D0Z3RF

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP formation (cAMP form)	TT0QZ8R	NOUNIPROTAC	Modulator	[2]

References

• [1] Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
• [2] ucb 11056, a new potential nootropic drug, amplifies induced cyclic AMP formation in rat brain tissue. J Neurochem. 1993 Dec;61(6):2256-61.